Shanghai: Dark Horse Consulting Group ('DHCG'), a leader in biotherapeutics consulting, and Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in Advanced Therapy Medicinal Products (ATMPs), have announced the signing of a Memorandum of Understanding (MOU). This strategic collaboration aims to accelerate the development and clinical translation of cell and gene therapies on a global scale.

According to BERNAMA News Agency, this partnership combines DHCG's extensive expertise in regulatory, CMC, nonclinical, clinical, quality and compliance, supply chain, commercial launch, and business analytics consulting with Porton Advanced's comprehensive GMP manufacturing infrastructure. The infrastructure covers lentiviral vectors, AAV, mRNA/LNP, plasmids, and engineered cell therapies, including CAR-T, CAR-NK, and iPSC-derived products.

Together, DHCG and Porton Advanced will offer client companies a cost-effective and expedited pathway into clinical-stage manufacturing, with a particular focus on facilitating Investigator-Initiated Trials (IITs) in China. This collaboration represents a significant step forward in the global advancement of cell and gene therapies, providing streamlined processes and expertise for companies aiming to enter the Chinese market.